Dear Mr. Miranda:

Please refer to your supplemental new drug application dated October 22, 2008, received October 22, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Gleevec® (imatinib mesylate) Tablets, 100 mg and 400 mg.

We also refer to our supplement request letter dated September 26, 2008.

We acknowledge receipt of your submission dated December 17, 2008.

This supplemental new drug application provides for revising the Adverse Reactions section of the Package Insert to replace terms such as “rare”, “uncommon”, “common”, etc. and supporting data.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at [http://www.fda.gov/oc/datacouncil/spl.html](http://www.fda.gov/oc/datacouncil/spl.html) that is identical to the enclosed labeling (text for the package insert). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, “SPL for approved NDA 21-588/S-027.”
DEAR HEALTH CARE PROFESSIONAL LETTER

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

Please submit an updated labeling to S-026.

If you have any questions, call Susan Jenney, Regulatory Project Manager, at (301) 796-0062.

Sincerely,

{See appended electronic signature page}

Robert Justice, M.D.
Division Director
Division of Drug Oncology Products
Office of Drug Oncology Products
Center of Drug Evaluation and Research

Enclosure (Package Insert)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

\(/
\text{s/}\)

----------------------
Robert Justice
2/10/2009 06:39:37 PM